Related Experiment Video
Updated: Jan 3, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma
Ankur K Nagaraja1, Osamu Kikuchi1, Adam J Bass2,3,4
1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Abstract:
Gastroesophageal adenocarcinomas (GEA) are devastating diseases with stark global presence. Over the past 10 years, there have been minimal improvements in treatment approach despite numerous clinical trials. Here, we review recent progress toward understanding the molecular features of these cancers and the diagnostic and therapeutic challenges posed by their intrinsic genomic instability and heterogeneity. We highlight the potential of genomic heterogeneity to influence clinical trial outcomes for targeted therapies and emphasize the need for comprehensive molecular profiling to guide treatment selection and adapt treatment to resistance and genomic evolution. Revising our clinical approach to GEA by leveraging genomic advances will be integral to the success of current and future treatments, especially as novel targets become therapeutically tractable. SIGNIFICANCE: GEAs are deadly cancers with few treatment options. Characterization of the genomic landscape of these cancers has revealed considerable genetic diversity and spatial heterogeneity. Understanding these fundamental properties of GEA will be critical for overcoming barriers to the development of novel, more effective therapeutic strategies.
Insights
Gastroesophageal adenocarcinomas (GEA) are aggressive cancers with limited treatment progress. Understanding their genomic diversity is key to developing effective targeted therapies and improving patient outcomes.
Area of Science:
- Oncology
- Genetics
- Cancer Biology
Background:
- Gastroesophageal adenocarcinomas (GEA) represent a significant global health burden with minimal therapeutic advancements in the last decade.
- Numerous clinical trials have yielded limited improvements, underscoring the need for novel treatment strategies.
Purpose of the Study:
- To review recent molecular insights into GEA.
- To discuss the challenges posed by genomic instability and heterogeneity in GEA diagnosis and treatment.
- To emphasize the importance of molecular profiling for guiding therapy and overcoming resistance.
Main Methods:
- Literature review of recent progress in understanding GEA molecular features.
- Analysis of diagnostic and therapeutic challenges related to genomic heterogeneity.
- Discussion of the impact of genomic diversity on targeted therapy clinical trials.
Main Results:
- GEA exhibits significant genetic diversity and spatial heterogeneity.
- Genomic heterogeneity can impact the efficacy of targeted therapies in clinical trials.
- Comprehensive molecular profiling is essential for personalized treatment selection and adaptation.
Conclusions:
- Understanding the genomic landscape of GEA is critical for developing effective therapeutic strategies.
- Leveraging genomic advances is integral to improving outcomes for current and future GEA treatments.
- Addressing genomic heterogeneity is paramount to overcoming barriers in GEA treatment development.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers